The ACOD1 Knockout A-549 Polyclonal Cells provide a CRISPR/Cas9-edited polyclonal knockout cell population derived from the A-549 human lung adenocarcinoma epithelial cell line, designed for loss-of-function studies of the ACOD1 gene. This polyclonal population consists of a heterogeneous mixture of edited cells with targeted disruption of ACOD1, offering a robust model to dissect itaconate-dependent immunometabolic pathways in a cancer-relevant epithelial context without the need for clonal isolation.
The A-549 cell line was originally established from a 58-year-old Caucasian male with lung carcinoma and is widely used as a model for non-small cell lung cancer (NSCLC). These cells exhibit an adherent epithelial morphology, are wild-type for EGFR, and harbor a KRAS G12S activating mutation, which drives oncogenic signaling. As an alveolar epithelial-derived line, A-549 cells retain key features of type II pneumocytes, making them suitable for studying lung cancer biology, inflammation, and host-pathogen interactions. The presence of the KRAS mutation provides a genetically defined context for exploring metabolic vulnerabilities and immune responses in NSCLC.
ACOD1 catalyzes the decarboxylation of cis-aconitate to produce itaconate, an immunometabolite with anti-inflammatory and antimicrobial properties. Its expression is induced by pro-inflammatory stimuli including LPS, IFN-??, TNF-??, and poly(I:C) via transcription factors NF-??B, IRF1, STAT1, and AhR. Itaconate inhibits SDH, remodels the TCA cycle, and activates Nrf2 by alkylating KEAP1. It also blocks NLRP3 inflammasome assembly and modulates ATF3, GAPDH, MAVS, TET2, and I??B??, orchestrating a broad anti-inflammatory program.
In the context of A-549 cells, ACOD1 knockout provides a powerful tool to probe the intersection of inflammation and metabolism in NSCLC. KRAS-mutant lung cancers often display altered metabolic states and immune evasion strategies; loss of ACOD1 may enhance inflammatory signaling, alter mitochondrial metabolism, and impact tumor cell-intrinsic immune responses. This model can be used to investigate how itaconate production influences cancer cell proliferation, survival, and sensitivity to immune-mediated killing. Moreover, by deleting ACOD1 in an alveolar epithelial background, researchers can study the role of pulmonary epithelial cells in shaping innate immunity during infections such as bacterial pneumonia or viral challenges, where ACOD1 is known to restrict pathogen replication.
Researchers can employ the ACOD1 Knockout A-549 Polyclonal Cells for a variety of applications, including immunometabolism research, anti-inflammatory drug screening, and host-pathogen interaction studies. The absence of ACOD1 enables direct assessment of itaconate-dependent effects using complementary assays such as LC-MS?Cbased itaconate quantification, SDH activity measurements, and Nrf2 luciferase reporter assays. Additional applications include CRISPR-based functional genomics, NF-??B luciferase assays, metabolic flux analysis, and bacterial killing assays. This polyclonal knockout model supports detailed mechanistic investigations into ACOD1-regulated pathways in lung adenocarcinoma and inflammation biology. For additional information, please contact Ascent Research.
